<DOC>
	<DOCNO>NCT01774435</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , PK EN3342 implantation duration 6 month .</brief_summary>
	<brief_title>Study Stabilized Schizophrenic Patients Evaluate Pharmacokinetics Risperidone 9-Hydroxy ( OH ) -Risperidone When Risperidone Administered From Polyurethane Implant</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Subject Inclusion Criteria 1 . Subject ( and/or subject 's authorized legal representative ) provide write informed consent 2 . Subject identify caregiver personal contact subject significant contact least per week 3 . Subject male female nonchild bear potential 18 60 year age inclusive 4 . Subject diagnosis schizophrenia accord DSMIV criterion 5 . Subject body mass index ( BMI ) ≥18.5 ≤35.0 kg/m2 6 . Subject assess symptomatically stable Investigator , regard psychiatric condition 7 . Subject assessed Investigator symptomatically stable regard pre exist medical condition evidence medical history , clinically significant finding physical examination , vital sign , clinical laboratory evaluation ( hematology , serum chemistry , urinalysis ) 12lead electrocardiogram ( ECG ) . Subjects may continue current medication regimen control preexist medical psychiatric ( schizophrenia ) condition include use PRN medication . 8 . Subject currently stable 4 , 6 , 8mg oral dose risperidone 30 day prior admission Subject Exclusion Criteria 1 . Known hypersensitivity allergy lidocaine local anesthetic agent amide type ( local anesthetic use implant explant procedure ) 2 . Known sensitivity polyurethane 3 . Hospitalized required acute crisis intervention symptom exacerbation 30 day prior admission determine Investigator 4 . Subject history suicide attempt last year , opinion investigator currently imminent risk suicide 5 . Reports reveals presence clinically significant skin disorder ( , limit , skin cancer , psoriasis , eczema , atopic dermatitis ) , evidence recent sunburn , scar tissue , tattoo , open sore , body pierce brand intend implantation site would interfere implantation procedure interfere implant site assessment determine Investigator 6 . History abnormal scar formation family history keloid formation 7 . Have positive screen substance abuse conduct screen history abuse last six month define DSMIV criterion 8 . Have impair hepatic ( ALT/AST &gt; 1.5 time high upper limit normal ) renal function ( eGFR &lt; 50mL/min ) 9 . Previously define hypersensitivity risperidone 10 . History neuromalignant syndrome ( NMS ) 11 . Electroconvulsive therapy within 6 month admission 12 . Treatment coexist medical condition require introduction cytochrome P450 2D6 inhibitor inducer 13 . Positive screen Hepatitis B Surface Antigen ( HBsAg ) , Hepatitis C Antibody ( anti HCV ) , human immunodeficiency virus ( HIV ) antibody and/or antigen 14 . Participation treatment phase clinical study receipt investigational drug within 30 day prior study drug administration Day 1 ; investigational drug elimination halflife great 15 day , time period extend 60 day 15 . Prior participation EN3342 study 16 . Involvement plan and/or conduct study ( applies Endo staff staff investigational site ) 17 . History difficulty phlebotomy procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophrenic</keyword>
	<keyword>Stable Schizophrenic</keyword>
</DOC>